SINGAPORE (August 5th, 2025) – Hongene, a global CDMO focused on nucleic acid raw materials and medicines, has appointed Dr. Pieter Cullis, a renowned innovator in lipid nanoparticle (LNP) drug delivery, to its scientific advisory board. This strategic addition reinforces Hongene’s commitment to advancing RNA therapeutics.
Dr. Cullis is widely recognized for his foundational contributions to LNP technology, including its application in mRNA and siRNA therapeutics. His innovations have played a central role in the development of several FDA-approved therapies, most notably the Pfizer-BioNTech COVID-19 vaccine.
Dr. Cullis will advise on Hongene’s proprietary technologies including drug delivery and mRNA optimization, as the company advances its nucleic acid capabilities and services.
“I am excited to join Hongene’s scientific advisory board and contribute to its mission of providing access to RNA medicines for all people, regardless of their income or where they live,” said Dr. Cullis. “I look forward to collaborating with the team to enable this.”
Dr. Cullis joins an esteemed group of scientific leaders, including Dr. John Maraganore, Dr. Phil Baran, and Dr. Masad J. Damha. The board will guide Hongene’s innovation strategy and accelerate the company’s efforts to support clients developing RNA drugs with groundbreaking technologies.
“We are honored to welcome Dr. Cullis to our advisory board,” said Wei Jiang, CEO of Hongene. “His scientific contributions and thought leadership in LNP delivery systems are unparalleled and will significantly boost our work in RNA therapeutics.”
This appointment comes as RNA medicines experience accelerating adoption across a broad range of rare and common genetic indications. With expert insights from Dr. Cullis and fellow advisors, Hongene is poised to deliver vertically integrated CDMO solutions that support next-generation nucleic acid therapeutics from concept to commercialization.
To learn more about Hongene, visit hongene.com or contact info@hongene.com.
About Hongene
Hongene is a leading CDMO serving the global nucleic acid therapeutics industry. The company offers end-to-end support across oligonucleotide design, synthesis, analytics and scale-up, enabling clients to progress rapidly from discovery through commercialization.
